Monday, June 21, 2010
Inc. believes G protein-coupled receptor ligands that target just one
GPCR pathway could provide either better efficacy or fewer side effects than
ligands that agonize or antagonize the whole receptor. The company is raising a
series B round to build a portfolio of what it calls biased ligands.
GPCR signaling is mediated
through two pathways: the G protein pathway and the beta arrestin pathway. The
G protein pathway actively signals to elicit a biological response. The beta
arrestin pathway has a dual role, both as an off-switch for G protein
signaling, and as an active biological signaling pathway itself.